PQ Pharmacy, LLC
Has PQ Pharmacy, LLC received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued PQ Pharmacy, LLC a warning letter naming semaglutide, dated Oct 10, 2025, with the FDA subject line “Compounding Pharmacy/Adulterated Drug Products.”
FDA records in this index name PQ Pharmacy, LLC on Oct 10, 2025. It is listed on FDA’s registered 503B outsourcing facility list: PQ Pharmacy LLC, Brooksville, FL.
- Type named in FDA records
- Compounding pharmacy, 503B outsourcing facility
- FDA warning letters
- 1
- Drug recall reports
- 0
- Drugs named
- Semaglutide
- Latest record
- Oct 10, 2025
- 503B location
- Brooksville, FL
- 503B last inspection
- Jun 1, 2026
- Form 483 issued
- Yes
- Action on last inspection
- Open
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Oct 10, 2025 | Compounding Pharmacy/Adulterated Drug Products | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Oct 10, 2025: … HCl/Bromfenac PF PMB032025EO1 (8.6mL) 3/28/2025 Semaglutide 5mg vials SEM032525JP 3/28/2025 3. Your smoke … Full letter
Drug recalls
No openFDA drug recall reports in this index.
FDA compounding inspections and actions
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.
PQ Pharmacy, LLC, Brooksville, FL (503B)
6 listed actions, including 4 Form 483s and 1 warning letter (2022 to 2026).
| Document | |||
|---|---|---|---|
| Jun 1, 2026 | Form 483 | 483 Issued 06/01/2026 | fda.gov |
| Oct 10, 2025 | Warning letter | Warning Letter (10/10/2025) | fda.gov |
| Apr 4, 2025 | Form 483 | 483 issued 04/04/2025 | fda.gov |
| Mar 30, 2023 | FMD-145 letter | FMD-145 Letter Issued 3/30/2023 | Not linked by FDA |
| Nov 17, 2022 | Amended Form 483 | Amended 483 Issued 11/17/2022 | FDA copy (archived) |
| Oct 27, 2022 | Form 483 | 483 Issued 10/27/2022 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: PQ Pharmacy LLC, Brooksville, FL.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 7 products naming liraglutide, semaglutide and tirzepatide under the labeler name “PQ Pharmacy LLC”, matched to this company page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (7). The compounded product reports cover FDA reporting periods 2024-2 to 2025-2.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 81375-606 | Liraglutide | Liraglutide | INJECTION | SUBCUTANEOUS | 6 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2 | Compounded drugs |
| 81375-614 | Liraglutide | Liraglutide | INJECTION | SUBCUTANEOUS | 15 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2 | Compounded drugs |
| 81375-600 | Semaglutide | Semaglutide 2.5mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81375-601 | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81375-605 | Semaglutide | Semaglutide 5mg/mL | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81375-610 | Tirzepatide | Tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81375-620 | Tirzepatide | Tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, Oct 10, 2025
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA warning letters (fda.gov full-text search)
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.